SUPN

Supernus Pharmaceuticals Inc

NASDAQ

Add Alert

SUPN

Supernus Pharmaceuticals Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

ncstrongman

04/11/22 8:49 AM

Post #138

Just found this one - Well over a year since last posts...why is that ? Seems like a solid stock

ball8281

12/22/20 8:24 PM

Post #137

I hope everyone got some 28 es because tomorrow we gap hard and run for the. Boarder get your shares at open

ball8281

12/22/20 8:23 PM

Post #136

Wow that’s amazing news tomorrow gap up will be amazing

ball8281

12/22/20 8:22 PM

Post #135

Boom we’re heading to 50 dollars a share tomorrow

Diwanssong

11/06/20 11:54 AM

Post #134

Re: #131: @dinogreeves - 30-35 dollars easy tomorrow with this awesome earnings

what about the PDUFA on the 8th? will it be delayed? what do u expect the PPS if it is approved/

whytestocks

11/04/20 1:45 PM

Post #133

NEWS: $SUPN Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q3 2020 Earnings Call Nov 4, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Trans...

Read the whole news SUPN - Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Transcript

dinogreeves

11/04/20 9:55 AM

Post #132

SUPN will easily be over 50 dollars on Monday after PDUFA comes out this weekend, you have to been in by Friday. Good luck.

dinogreeves

11/03/20 6:36 PM

Post #131

30-35 dollars easy tomorrow with this awesome earnings beat. Way undervalued on all fronts. Sitting on 5000 shares.

ClayTrader

11/06/19 5:28 PM

Post #130

* * $SUPN Video Chart 11-06-19 * *

Link to Video - click here to watch the technical chart video

ClarkKant

09/19/17 10:43 AM

Post #129

$SUPN on watch for bottom to drop out sub $40

joegrantjr

04/07/17 2:04 PM

Post #128

https://stocknews.com/news/supn-cantor-fitzgerald-reiterates-overweight-rating-31-pt-11867294/

cars100cars

04/07/17 8:46 AM

Post #127

Re: #126: @Chuck87 - Big news AH. Go SUPN

SUPN continues to be a big winner. Just look at the prescription growth in the last three years. With this indication now added on label, continued growth is ahead. SUPN customers require long term drug therapy. Investors can't ask for a better situation. The pipeline continues to look good, too.

Chuck87

04/05/17 8:38 PM

Post #126

Re: #125: @cars100cars - Great Conference Call and Another Big Growth Year

Big news AH. Go SUPN

cars100cars

03/10/17 2:16 PM

Post #125

Re: #124: @H2R - Positive SA article on SUPN:

Great Conference Call and Another Big Growth Year in 2016 -- The FDA approval of the migraine indication is about to happen. This company has a solid ongoing revenue stream that will expand significantly in 2017 and likely again for the next several years. The reason is simple. SUPN has "customers for life." The nonsense in Washington has little effect as these customers require constant daily medication. SUPN's epilepsy franchise is strong with Oxtellar XR, an extended-release oxcarbazepine; and Trokendi XR, an extended-release topiramate. Epilepsy patients and their docs appreciate the minimize side effects that this mandatory medicine has. The ADHD drug pipeline holds significant potential, too. This is a very important need, too. Prescriptions for Oxtellar and Trokendi continue to grow nicely, with patent protection exclusivity until 2023. There is a long clear runway to ramp up revenues ahead for SUPN when you look at the facts...not news blubs. With a forward P/E under 16 and quarterly revenue growth of 40+%, SUPN continues to be an investment gem, despite the day traders playing with the price around quarterly report time. SUPN is going higher.

H2R

01/05/17 4:58 PM

Post #124

Positive SA article on SUPN:
http://seekingalpha.com/article/4034630-supernus-pharmaceuticals-offers-rare-opportunity-investors

Summary

Supernus is a biotech firm with approved products..

Sales from these products are growing at an impressive rate..

The stock is underfollowed by analyst and may still be "under the radar"..

The company offers a promising pipeline with two compounds in Phase II/Phase III clinical trials.

Introduction

Supernus Pharmaceuticals (NASDAQ:SUPN) is a rarity among the thousands of publicly-traded biotechnology firms; it has approved products, revenue and earnings. While the company's sales are growing at a double digit rate, it also has promising drug candidates working their way through late-stage clinical trials. Preliminary results from these trials have been positive, and both compounds offer substantial revenue potential if approved. With a promising pipeline, strong top and bottom line growth and only a handful of analysts covering the stock, Supernus' stock may be poised to continue its market-beating performance.

Long SUPN

cars100cars

11/04/16 12:06 PM

Post #123

Re: #121: @Samsa - Really, I cant believe no one is following

No reason for SUPN to sell off. FDA approval for migraine indication is only four months away. This should add significant sales. Also, existing prescription sales continue to grow. Plus all active FDA trials continue to look good. Can't find any negatives to SUPN's fundamentals. Puzzling dip in price.

crudeoil24

10/11/16 8:51 AM

Post #122

Supernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD
Now - DJNF
Supernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD
-- Study confirms efficacy and tolerability of SPN-812, a novel

non-stimulant product, in children with ADHD

-- Study meets primary endpoint with statistically significant reduction in

ADHD symptoms

-- Conference call and webcast to discuss results at 9:00 a.m. ET, October

11, 2016

ROCKVILLE, Md., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from its Phase IIb dose-ranging clinical trial of SPN-812 in children for the treatment of attention deficit hyperactivity disorder (ADHD).

The trial was successful in meeting the primary endpoint, demonstrating that SPN-812 at daily doses of 400 mg, 300 mg and 200 mg achieved a statistically significant improvement in the symptoms of ADHD from baseline to end of study as measured by the ADHD Rating Scale-IV. All SPN-812 doses tested in the trial were well tolerated. Based on these positive results in children with ADHD and the positive Phase IIa results in adults with ADHD, Supernus plans to have an end-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) after which it will initiate Phase III clinical testing.

"We are very excited about these results and that SPN-812 met the objectives of the study with an encouraging and strong clinical profile, " stated Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. "We believe SPN-812 has the potential of being a well differentiated treatment for ADHD that sets itself apart from current treatment options."

Phase IIb Study Design

The study was a randomized, double-blind, placebo controlled, multicenter, dose-ranging clinical trial in children 6 to 12 years of age diagnosed with ADHD. Each treatment was administered orally once a day over five weeks, after a three week titration phase. A total of 222 patients were randomized in the study across placebo and four doses of SPN-812 (100/200/300/400mg). The primary objective of the study was to assess the effect of SPN-812 in reducing the symptoms of ADHD in children. The primary outcome measure was the change from baseline to the end of the study in the ADHD-RS-IV total score. Safety and tolerability of SPN-812 were assessed by the monitoring of adverse events, clinical laboratory tests, vital signs, ECGs, suicidality and physical examinations. Patients who completed the study were offered the opportunity to continue into an open-label phase that is currently on-going.

Topline Results

At the end of the study, SPN-812 400 mg, 300 mg and 200 mg doses were statistically significant compared to placebo in the primary endpoint. Patients receiving SPN-812 400 mg, 300 mg and 200 mg had a -19.0 point change (p=0.021), -18.6 point change (p=0.027) and a -18.4 point change (p=0.031) from baseline, respectively, in the primary endpoint vs. -10.5 for placebo.

This primary analysis using the Intent-To-Treat (ITT) population with last observation carried forward (LOCF) was confirmed with sensitivity analyses using the Per Protocol population and Mixed Model Repeated Measures (MMRM).

With respect to the effect size, patients receiving SPN-812 400 mg, 300 mg and 200 mg had a median effect size of 0.63, 0.60 and 0.55, respectively. Patients receiving SPN-812 100 mg had a -16.7 point change from baseline in the primary endpoint and a median effect size of 0.46, which did not quite reach statistical significance (p=0.089) in this relatively low number of patients.

In addition, SPN-812 400 mg, 300 mg and 200 mg met the Clinical Global Impression Severity (CGI-S) secondary endpoint with p- values of 0.014, 0.015 and 0.031, respectively, compared to placebo.

"These results exhibit a strong clinical efficacy profile with effect sizes that are typically not seen with non-stimulants. In addition, of the 160 patients who completed the trial, 87% or 139 patients chose to enter the open-label phase showing a high level of confidence in SPN-812," stated Dr. Stefan Schwabe, Executive Vice President R&D, Chief Medical Officer of Supernus Pharmaceuticals.

SPN-812 was well tolerated in the study. All four active doses were well tolerated, with adverse events almost entirely mild or moderate in severity. Two subjects experienced three adverse events that were classified as severe and related to the medication; one on 400 mg with easy tearfulness and intermittent irritability and another on 200 mg with decreased appetite. There were no serious adverse events or deaths in the study. The most frequent adverse events across all the active doses were primarily somnolence, headache, decreased appetite, fatigue, vomiting and nausea. On average, the percentage of patients discontinuing the study due to adverse events for all active doses of SPN-812 was low at 6.7%.

"We believe this side effect profile compares very well with existing treatments in the market," added Dr. Schwabe.

Product Pipeline

SPN-812 is the company's second psychiatry product in late stage development. Supernus is also developing SPN-810 (molindone hydrochloride), a novel treatment for impulsive aggression in patients with ADHD. SPN-810 is currently in clinical development with two Phase III trials in children with ADHD.

"We are excited about our psychiatry pipeline, with two late-stage novel product candidates with positive Phase II clinical results. With SPN-812 now proceeding towards Phase III clinical testing, Supernus expects to have two product candidates in Phase III testing in 2017. We believe these two product candidates represent a significant platform for future growth for Supernus in multi-billion dollar markets," added Jack Khattar.

Samsa

09/16/16 12:43 PM

Post #121

Really, I cant believe no one is following this on here.

thetechtrader

06/29/16 6:35 AM

Post #120

Harry has posted Charts of the Day video on SUPN at TheTechTrader site noting:Supernus Pharmaceuticals, Inc. (SUPN) is one of the better junior biotech’s. The Feb low was under 10, and now it has gotten up to 20, more than doubling in that amount of time and in multiple waves. On Tuesday it was up 1.01 to 19.06, or 5.6%, on 425,492 shares traded. It may very well be headed toward the 20-21 zone, even as high as 23 short-term. It has 5.6 days to cover. http://tinyurl.com/j7gr482

thetechtrader

06/29/16 6:31 AM

Post #119

thetechtrader

06/29/16 6:31 AM

Post #118

thetechtrader

05/25/16 9:01 AM

Post #117

Harry has posted Charts of the Day video on SUPN at TheTechTrader site noting:Supernus Pharmaceuticals, Inc. (SUPN) continues moving in a rising channel, up 44 cents to 18.85, or 2.39%, on 431,200 shares traded. It has taken out resistance and may very well test 19.25but more importantly 20-201/2. It has 4.9 days to cover.